Universal Sequencing Technology

Universal Sequencing Technology is a private, commercial-stage biotech firm specializing in genomics tools that enhance the capabilities of standard short-read sequencing platforms. Its core innovation, TELL-Seq, allows researchers to obtain long-range genomic information (up to 200kb+) from Illumina and similar systems, simplifying applications like de novo assembly, phasing, and metagenomics. The company has a co-marketing relationship with Illumina and generates revenue through the sale of library prep kits and related software, positioning it in the competitive but high-growth NGS market. UST's strategy focuses on making advanced genomic analysis more accessible and cost-effective for a broad research audience.

TELL-Seq (Transposase Enzyme-Linked Long-read Sequencing) for generating barcode linked-reads on short-read platforms, and AmpliDrop for microfluidics-free single-cell library preparation.

UST competes in the long-range genomics space against 10x Genomics' (legacy) linked-read technology and direct long-read platforms from PacBio and Oxford Nanopore. In single-cell, it faces established microfluidics-based players like 10x Genomics, BD, and Parse Biosciences. Its differentiation is low-cost, simplicity, and leveraging existing Illumina workflows.